



(Please scan this QR Code to view the RHP)

This is an abridged prospectus containing salient features of the red herring prospectus of Park Medi World Limited (the “Company”) dated December 04, 2025 filed with the Registrar of Companies, Delhi and Haryana at New Delhi (the “RHP” or “Red Herring Prospectus”). You are encouraged to read greater details available in the RHP, which is available at <https://www.sebi.gov.in/sebiweb/home/HomeAction.do?doListing=yes&sid=3&ssid=15&smid=11>. Unless otherwise specified all capitalized terms used herein and not specifically defined shall bear the same meaning as ascribed to them in the RHP. This abridged prospectus is not for distribution outside India.

THIS ABRIDGED PROSPECTUS CONSISTS OF FOUR PAGES OF BID CUM APPLICATION FORM ALONG WITH INSTRUCTIONS AND EIGHT PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

Please ensure that you have read the RHP, the preliminary international wrap dated December 04, 2025 (“together with the RHP the “Preliminary Offering Memorandum”) (if outside India), this abridged prospectus (“Abridged Prospectus”) and the general information document (“GID”) for investing in public offers undertaken through the Book Building Process before applying in the Offer. The investors are advised to retain a copy of the RHP/Abridged Prospectus for their future reference. You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges, Syndicate Members, the Registrar to the Offer, Registrar and Share Transfer Agents (“RTAs”), Collecting Depository Participants (“CDPs”), Registered Brokers, Underwriters, bankers to the Offer, Self Certified Syndicate Banks (“SCSBs”). You may also download the RHP from the website of Securities and Exchange Board of India (“SEBI”) at www.sebi.gov.in, at the websites of National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”, and together with NSE, the “Stock Exchanges”) at www.nseindia.com and www.bseindia.com, respectively, and the website of our Company at www.parkhospital.in and the websites of the Book Running Lead Managers at www.nuvama.com, www.india.cla.com, www.damcapital.in and www.intensivefiscal.com respectively.



PARK MEDI WORLD LIMITED

Corporate Identity Number: U85110DL2011PLC212901; **Date of Incorporation:** January 20, 2011

REGISTERED OFFICE	CORPORATE OFFICE	CONTACT PERSON	EMAIL AND TELEPHONE	WEBSITE
12, Meera Enclave Near Keshopur, Bus Depot, Outer Ring Road, New Delhi 110 018, Delhi	Park Tower, Plot no. 521, Udyog Vihar Phase 3, Gurugram 122 022, Haryana	Abhishek Kapoor Company Secretary and Compliance Officer	Email: company.secretary@parkhospital.in Telephone: + 91 124 696 0000	www.parkhospital.in

OUR PROMOTERS: DR. AJIT GUPTA AND DR. ANKIT GUPTA

DETAILS OF THE OFFER TO THE PUBLIC							
Type of Offer	Fresh Issue size	Offer for Sale size	Total Offer size	Eligibility	Share reservation among QIBs, NIBs and RIBs		
					QIBs	NIBs	RIBs
Fresh Issue and Offer for Sale	Up to [●] Equity Shares of face value of ₹ 2 each aggregating up to ₹ 7,700.00 million	Up to [●] Equity Shares of face value of ₹ 2 each aggregating up to ₹ 1,500.00 million	Up to [●] Equity Shares of face value of ₹ 2 each aggregating up to ₹ 9,200.00 million	The Offer is being made pursuant to Regulation 6(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“SEBI ICDR Regulations”). For further details, see “Other Regulatory and Statutory Disclosures – Eligibility for the Offer” on page 500 of the RHP. For details in relation to the share allocation and reservation among, Qualified Institutional Buyers (“QIBs”), Retail Individual Bidders (“RIBs”), Non-Institutional Bidders (“NIBs”), see “Offer Structure” on page 519 of the RHP.	Not more than 50% of the Offer being available for allocation to QIB Bidders. However, 5% of the Net QIB Portion (excluding the Anchor Investor Portion) will be available for allocation proportionately to Mutual Funds only.	Not less than 15% of the Offer or the Offer less allocation to QIB Bidders and RIBs.	Not less than 35% of the Offer, or the Offer less allocation to QIB Bidders and NIBs.

The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the stock exchanges being BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”, and together with the BSE, the “Stock Exchanges”). NSE is the Designated Stock Exchange (the “Designated Stock Exchange”).

DETAILS OF THE OFFER FOR SALE			
Name of the Promoter Selling Shareholder	Type	Number of Equity Shares Offered / Amount (In ₹ Million)	Weighted Average Cost of Acquisition (In ₹ Per Equity Share)#
Dr. Ajit Gupta	Promoter Selling Shareholder	Up to [●] Equity Shares of face value of ₹ 2 each aggregating up to ₹ 1,500.00 million	0.08

As certified by Agiwal & Associates, Chartered Accountants, by way of their certificate dated December 04, 2025.

PRICE BAND, MINIMUM BID LOT & INDICATIVE TIMELINES	
Price Band [^]	₹ 154 per Equity Share to ₹ 162 per Equity Share of face value of ₹ 2 each
Minimum Bid Lot Size	A Minimum of 92 Equity Shares and in multiples of 92 Equity Shares thereafter
Anchor Investor Bid/Offer Period	Tuesday, December 09, 2025
Bid/Offer Opens On	Wednesday, December 10, 2025
Bid/Offer Closes On	Friday, December 12, 2025 [^]
Finalisation of Basis of Allotment with the Designated Stock Exchange	On or about Monday, December 15, 2025
Initiation of refunds (if any, for Anchor Investors) / unblocking of funds from ASBA Account*	On or about Tuesday, December 16, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or about Tuesday, December 16, 2025
Commencement of trading of the Equity Shares on the Stock Exchanges	On or about Wednesday, December 17, 2025

[^] UPI mandate end time and date shall be at 5:00 pm IST on Bid/ Offer Closing Date, i.e. Friday, December 12, 2025.

* In case of (i) any delay in unblocking of amounts in the ASBA Accounts (including amounts blocked through the UPI Mechanism) exceeding two Working Days from the Bid/Offer Closing Date for cancelled/ withdrawn/ deleted ASBA Forms, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher from the date on which the request for cancellation/ withdrawal/ deletion is placed in the Stock Exchanges bidding platform until the date on which the amounts are unblocked (ii) any blocking of multiple amounts for the same ASBA Form (for amounts blocked through the UPI Mechanism), the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the total cumulative blocked amount except the original application amount, whichever is higher from the date on which such multiple amounts were blocked till the date of actual unblock; (iii) any blocking of amounts more than the Bid Amount, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the difference in amount, whichever is higher from the date on which such excess amounts were blocked till the date of actual unblock; (iv) any delay in unblocking of non-allotted/ partially allotted Bids, exceeding two Working Days from the Bid/Offer Closing Date, the Bidder shall be compensated at a uniform rate of ₹100 per day or 15% per annum of the Bid Amount, whichever is higher for the entire duration of delay exceeding two Working Days from the Bid/ Offer Closing Date by the SCSB responsible for causing such delay in unblocking. The BRLMs shall, in their sole discretion, identify and fix the liability on such intermediary or entity responsible for such delay in unblocking. The Bidders shall be compensated in the manner specified in the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021, as amended pursuant to SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021, and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022, read with SEBI master circular no. SEBI/HO/CFD/POD-1/P/CIR/2024/0154 dated November 11, 2024, which for the avoidance of doubt, shall be deemed to be incorporated in the deemed agreement of our Company with the SCSBs, to the extent applicable, issued by SEBI, and any other applicable law in case of delays in resolving investor grievances in relation to blocking/unblocking of funds. The processing fees for applications made by the UPI Bidders using the UPI Mechanism may be released to the remitter banks (SCSBs) only after such banks provide a written

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

confirmation on compliance with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022 and SEBI Circular No. SEBI/HO/CFD/DIL2/P/CIR/2022/75 dated May 30, 2022. SEBI through its circular (SEBI/HO/CFD/DIL2/CIR/P/2022/45) dated April 5, 2022, read with SEBI master circular no. SEBI/HO/CFD/POD-1/P/CIR/2024/0154 dated November 11, 2024, has prescribed that all individual investors applying in initial public offerings opening on or after May 1, 2022, where the application amount is up to ₹ 0.50 million, shall use UPI. RIBs and individual investors Bidding under the Non-Institutional Portion Bidding for more than ₹ 0.20 million and up to ₹ 0.50 million, using the UPI Mechanism, shall provide their UPI ID in the Bid-cum-Application Form for Bidding through Syndicate, sub-syndicate members, Registered Brokers, RTAs or CDPs, or online using the facility of linked online trading, demat and bank account (3 in 1 type accounts), provided by certain brokers. Further, the SEBI master circular no. SEBI/HO/CFD/POD-1/P/CIR/2024/0154 dated November 11, 2024 consolidated the aforementioned circulars and rescinded these circulars to the extent they relate to the SEBI ICDR Regulations. The processing fees for applications made by UPI Bidders may be released to the remitter banks (SCSBs) only after such banks provide a written confirmation on compliance with SEBI circular no. SEBI/HO/CFD/DIL2/P/CIR/2021/570 dated June 2, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2021/2480/1/M dated March 16, 2021 and SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/51 dated April 20, 2022.

WEIGHTED AVERAGE COST OF ACQUISITION OF ALL EQUITY SHARES TRANSACTED IN ONE YEAR, EIGHTEEN MONTHS AND THREE YEARS PRECEDING THE DATE OF THE RED HERRING PROSPECTUS:

Period	Weighted Average Cost of Acquisition (in ₹)**	Cap Price is 'X' times the Weighted Average Cost of Acquisition [§]	Range of acquisition price: Lowest Price – Highest Price (in ₹)
Last one year preceding the date of the Red Herring Prospectus	164.31	0.99	162.00-200.00
Last 18 months preceding the date of the Red Herring Prospectus	164.31	0.99	162.00-200.00
Last three years preceding the date of the Red Herring Prospectus	164.31	0.99	162.00-200.00

As certified by Agiwal & Associates, Chartered Accountants, by way of their certificate dated December 04, 2025.

*Pursuant to resolutions passed by our Board and our Shareholders dated February 13, 2025 and February 15, 2025, our Company has sub-divided two equity shares of face value of ₹5 each into five Equity Shares of face value of ₹2 each. The impact of the subdivision has been considered in the calculation of acquisition price per Equity Share.

§ Excluding transactions of gifts.

The Equity Shares have not been and will not be registered under the U.S. Securities Act or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in “offshore transactions” as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where those offers and sales are made.

RISKS IN RELATION TO THE FIRST OFFER

This being the first public issue of Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of each Equity Share is ₹2. The Floor Price, Cap Price and Offer Price as determined by our Company, in consultation with the Book Running Lead Managers (“BRLMs”), in accordance with the SEBI ICDR Regulations, and on the basis of the assessment of market demand for the Equity Shares by way of the Book Building Process as stated in “Basis for Offer Price” on page 150 of the RHP should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISK

Investments in equity and equity-related securities involve a degree of risk and Bidders should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have neither been recommended, nor approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the Bidders is invited to “Risk Factors” on page 35 of the RHP and on page 9 of this Abridged Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid cum Application Form and the RHP from the Stock Exchanges, Syndicate Members, Registrar to the Offer, RTAs, CDPs, Registered Brokers, Bankers to the Offer or SCSBs.

If you wish to know about processes and procedures applicable to the Offer, you may request for a copy of the RHP and/or the GID from the BRLMs or download it from the website of SEBI at www.sebi.gov.in, the websites of NSE and BSE at www.nseindia.com and www.bseindia.com, respectively, and the websites of the BRLMs at www.nuvama.com, www.india.clsa.com, www.damcapital.in and www.intensivefiscal.com, respectively.

PRICE INFORMATION OF BRLMs

Sr. No.	Issuer name	Name of Merchant Banker	+/- % change in closing price, [+/- % change in closing benchmark]		
			30th calendar days from listing	90th calendar days from listing	180th calendar days from listing
1.	Anand Rathi Share and Stock Brokers Limited	Nuvama, DAM Capital	24.03% [5.86%]	NA	NA
2.	Solarworld Energy Solutions Limited	Nuvama	-3.59% [5.86%]	NA	NA
3.	Jaro Institute of Technology Management and Research Limited	Nuvama	-32.12% [5.86%]	NA	NA
4.	Vikram Solar Limited	Nuvama	-1.48% [1.40%]	-13.25% [5.49%]	NA
5.	Sambhv Steel Tubes Limited	Nuvama	55.74% [-2.69%]	31.82% [-3.22%]	NA
6.	HDB Financial Services Limited	Nuvama	2.51% [-2.69%]	1.10% [-3.22%]	NA
7.	ArisInfra Solutions Limited	Nuvama	-33.84% [-0.72%]	-23.21% [-0.17%]	NA
8.	Oswal Pumps Limited	CLSA, Nuvama	17.96% [-0.57%]	29.28% [0.87%]	NA
9.	Unicommerce eSolutions Limited	CLSA	+109.98% [+3.23%]	+89.71% [+0.04%]	+39.56% [-2.40%]
10.	Juniper Hotels Limited	CLSA	+43.76% [+1.71%]	+21.22% [+4.47%]	+9.83% [+13.08%]
11.	Midwest Limited	DAM Capital, Intensive	+13.67% [+1.06%]	NA	NA
12.	TruAlt Bioenergy Limited	DAM Capital	-9.79% [+3.36%]	NA	NA
13.	Jain Resource Recycling Limited	DAM Capital	+71.37% [+4.19%]	NA	NA
14.	Ganesh Consumer Products Limited	DAM Capital	-12.05% [+5.30%]	NA	NA
15.	Saatvik Green Energy Limited	DAM Capital	+9.26% [+4.71%]	NA	NA
16.	Euro Pratik Sales Limited	DAM Capital	+4.35% [+2.78%]	NA	NA
17.	Lenskart Solutions Limited	Intensive	NA	NA	NA
18.	All Time Plastics Limited	Intensive, DAM Capital	-0.67% [+1.62%]	+1.82% [+4.06%]	NA

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

19.	Vishal Mega Mart Limited	Intensive	+39.96% [-3.67%]	+29.95% [-6.98%]	+58.58% [+2.15%]
20.	Waaree Energies Limited	Intensive	+68.05% [-0.59%]	+49.15% [-5.12%]	+78.80% [-1.23%]
21.	Bazaar Style Retail Limited	Intensive	-1.32% [+0.62%]	-16.11% [-0.28%]	-43.43% [10.09%]
22.	Gopal Snacks Limited	Intensive	-18.13% [+1.57%]	-19.35% [+4.60%]	-18.63% [+11.58%]

For further details, please refer to “Other Regulatory and Statutory Disclosures — Price information of past issues handled by the BRLMs” on page 506 of the RHP.

BOOK RUNNING LEAD MANAGERS

Nuvama Wealth Management Limited Telephone: + 91 22 4009 4400 Email: parkhospitals.ipo@nuvama.com Investor grievance email: customerservice.mb@nuvama.com	CLSA India Private Limited Telephone: + 91 22 6650 5050 E-mail: parkmediworld.ipo@clsa.com Investor Grievance ID: investor.helpdesk@clsa.com	DAM Capital Advisors Limited Telephone: +91 22 4202 2500 E-mail: parkhospitals.ipo@damcapital.in Investor Grievance ID: complaint@damcapital.in	Intensive Fiscal Services Private Limited Telephone: +91 22 2287 0443 E-mail: park.ipo@intensivefiscal.com Investor Grievance ID: grievance.ib@intensivefiscal.com
--	---	--	---

Name of Syndicate Member	Nuvama Wealth Management Limited, Tel: +91 22 4009 4400; E-mail: parkhospitals.ipo@nuvama.com/ prakash.boricha@nuvama.com/ Sheetal.Parab@nuvama.com; Website: www.nuvama.com; Contact Person: Prakash Boricha; SEBI Registration No.: INZ000166136 and Sharekhan Limited, Tel: +91 22 6750 2000, Email: pravin@sharekhan.com, Contact Person: Pravin Darji, Website: www.sharekhan.com SEBI Registration Number: INB231073330/INB011073351
Name of Registrar to the Offer	KFin Technologies Limited Tel: +91 40 6716 2222; E-mail: parkmedi.ipo@kfintech.com; Investor grievance e-mail: einward.ris@kfintech.com
Name of Statutory Auditor	Agiwal & Associates, Chartered Accountants
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture Trustee	Not Applicable
Self Certified Syndicate Bank(s) and mobile applications enabled for UPI Mechanism	The banks registered with SEBI, which offer the facility of ASBA services, (i) in relation to ASBA (other than through the UPI Mechanism), where the Bid Amount will be blocked by authorizing an SCSB, a list of which is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlId=34 or www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlId=35 and as updated from time to time and at such other websites as may be prescribed by SEBI from time to time, (ii) in relation to Bidders using the UPI Mechanism, a list of which is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlId=40 or such other website as may be prescribed by SEBI and updated from time to time. Applications through UPI in the Offer can be made only through the SCSBs mobile applications (apps) whose name appears on the SEBI website. A list of SCSBs and mobile applications, which are live for applying in public issues using UPI Mechanism is provided as Annexure ‘A’ to the SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2019/85 dated July 26, 2019. The list is available on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlId=43 and as updated from time to time and at such other websites as may be prescribed by SEBI from time to time.
Syndicate SCSB Branches	In relation to Bids (other than Bids by Anchor Investors and RIIs) submitted to a member of the Syndicate, the list of branches of the SCSBs at the Specified Locations named by the respective SCSBs to receive deposits of Bid cum Application Forms from the members of the Syndicate is available on the website of the SEBI at http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes&intmlId=35 , which may be and updated from time to time or any such other website as may be prescribed by SEBI from time to time. For more information on such branches collecting Bid cum Application Forms from the Syndicate at Specified Locations, see the website of the SEBI at http://www.sebi.gov.in/sebiweb/other/OtherAction.do?DoRecognised=yes&intmlId=35 or any such other website as may be prescribed by SEBI from time to time.
Registered Brokers	The list of the Registered Brokers, eligible to accept ASBA forms, including details such as postal address, telephone number, and email address, is provided on the websites of BSE and NSE at http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?expandable=3 and http://www.nseindia.com/products/content/equities/ipo/ipo_mem_terminal.htm , respectively, or such other websites as updated from time to time.
Details regarding website address(es)/ link(s) from which the investor can obtain a list of RTAs, CDPs and stock brokers who can accept applications from investors, as applicable	The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations, including details such as address, telephone number, and e-mail address, are provided on the websites of BSE and NSE at http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6 and http://www.nseindia.com/products/content/equities/ipo/asba_procedures.htm , respectively, or such other websites as updated from time to time. The list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as name and contact details, are provided on the websites of BSE and NSE at http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6 and http://www.nseindia.com/products/content/equities/ipo/asba_procedures.htm , respectively, or such other websites as updated from time to time. For further details, see “General Information” on page 88 of the RHP.

PROMOTERS OF OUR COMPANY

Sr. No.	Name	Individual/ Corporate	Experience and Educational Qualification / Corporate Information
1.	Dr. Ajit Gupta	Individual	Dr. Ajit Gupta is one of the Promoters, the Chairman and a Whole-Time Director of our Company. He holds a bachelor’s degree in medicine and surgery from the University College of Medical Sciences, University of Delhi. He is registered with the Medical Council of India since January 8, 1981 (i.e. 44 years ago). Prior to joining our Company, he was associated with Safdarjung Hospital as a junior resident and with Park Hospital and Sunil Nursing Home as a sole proprietor. He has been associated with our Company since January 20, 2011. He has more than 25 years of experience in nursing home and hospital business.
2.	Dr. Ankit Gupta	Individual	Dr. Ankit Gupta is one of the Promoters, and the Managing Director of our Company. He holds a bachelor’s degree in medicine and surgery from the Bharati Vidyapeeth Deemed University, Pune. He registered with the Delhi Medical Council on March 14, 2005. Prior to joining our Company, he has been associated with Park Hospital as head-operations. He has been associated with our Company since January 20, 2011 (except for a period of two months from May 10, 2024 to July 10, 2024). He has more than 20 years of experience in the medical profession.

For details in respect of the Promoters, please refer to “Our Promoters and Promoter Group” on page 344 of the RHP.

BUSINESS OVERVIEW AND STRATEGY

Company Overview: We are the second largest private hospital chain in North India with an aggregate bed capacity of 3,000 beds, and the largest private hospital chain in terms of bed capacity in Haryana with 1,600 beds located in the state as of March 31, 2025. (Source: CRISIL Report) We operate a network of 14 NABH accredited multi-super specialty hospitals under the 'Park' brand, each committed to providing high-quality and affordable medical services across a diverse range of specialties. As of September 30, 2025, we had a dedicated team of 1,014 doctors and 2,142 nurses across our hospitals, delivering clinical and patient care. We have increased our bed capacity from 2,550 beds as of March 31, 2023 to 3,250 beds as of September 30, 2025, and we currently have a pipeline of hospital expansion in Ambala, Panchkula, Rohtak, New Delhi, Gorakhpur and Kanpur.

Service Offering: We offer over 30 super specialty and specialty services, including internal medicine, neurology, urology, gastroenterology, general surgery, orthopedics and oncology.

Geographies Served: We operate a network of 14 hospitals across Haryana, Punjab, Rajasthan and New Delhi, with eight hospitals in Haryana, one hospital in New Delhi, three hospitals in Punjab and two hospitals in Rajasthan. The table below sets forth the state-wise breakdown of our revenue from operations in the periods indicated:

The table below sets forth the state-wise breakdown of our revenue from operations in the years indicated:

State	Six months ended September 30, 2025		Six months ended September 30, 2024		Fiscal 2025		Fiscal 2024		Fiscal 2023	
	Amount (in ₹ million)	Percentage of Revenue from Operations (%)	Amount (in ₹ million)	Percentage of Revenue from Operations (%)	Amount (in ₹ million)	Percentage of Revenue from Operations (%)	Amount (in ₹ million)	Percentage of Revenue from Operations (%)	Amount (in ₹ million)	Percentage of Revenue from Operations (%)
Haryana	5,584.60	69.06%	5,160.05	74.62%	10,232.34	73.43%	9,469.81	76.92%	10,527.47	83.91%
Punjab	1,295.04	16.01%	755.61	10.93%	1,706.33	12.24%	990.14	8.04%	49.23	0.39%
Rajasthan	705.74	8.73%	593.63	8.58%	1,183.67	8.49%	1,043.26	8.47%	977.53	7.79%
Delhi	496.62	6.14%	405.77	5.87%	813.36	5.84%	807.46	6.56%	991.72	7.90%
Uttar Pradesh*	4.56	0.06%	-	-	-	-	-	-	-	-
Total	8,086.57	100.00%	6,915.06	100.00%	13,935.70	100.00%	12,310.66	100.00%	12,545.95	100.00%

*Indicates revenue generated from out-patient services provided by Devina Derma Private Limited.

Key Performance Indicators (KPIs):

Set forth below are KPIs, as certified by Agiwal & Associates, Chartered Accountants through their certificate dated December 04, 2025, which have been used historically by our Company to understand and analyse the business performance, which in result, help us in analyzing the growth of various verticals in comparison to our listed peers, and other relevant and material KPIs of the business of the Company that have a bearing for arriving at the Basis for the Offer Price:

Particulars	Six month period ended September 30, 2025	Six month period ended September 30, 2024	Fiscal 2025	Fiscal 2024	Fiscal 2023
Bed Capacity (count) ⁽¹⁾	3,250	3,000	3,000	2,900	2,550
Number of Operational Beds (count) ⁽²⁾	3,050	2,800	2,800	2,700	2,400
Number of ICU beds (count) ⁽³⁾	870	805	805	775	700
Bed Occupancy Rate (%) ⁽⁴⁾	68.14%	62.25%	61.63%	59.81%	75.13%
ARPOB (INR) ⁽⁵⁾	27,105	25,674	26,206	24,919	24,575
ALOS (days) ⁽⁶⁾	6.35	6.66	6.53	6.73	6.97
In Patient Volume (count) ⁽⁷⁾	46,551	40,368	81,311	73,284	73,084
Out Patient Volume (count) ⁽⁸⁾	392,049	308,352	637,852	497,694	358,511
In Patient Revenue (INR Mn) ⁽⁹⁾	7,673.49	6,652.04	13,377.03	11,851.95	12,212.44
Out Patient Revenue (INR Mn) ⁽¹⁰⁾	345.17	252.87	540.88	438.69	311.31
Revenue from Operations (INR Mn) ⁽¹¹⁾	8,086.57	6,915.06	13,935.70	12,310.66	12,545.95
EBITDA (INR Mn) ⁽¹²⁾	2,171.36	1,895.94	3,721.73	3,103.01	3,903.41
EBITDA Margin (%) ⁽¹³⁾	26.85%	27.42%	26.71%	25.21%	31.11%
Restated profit after tax (INR Mn)	1,391.43	1,128.89	2,132.15	1,520.07	2,281.86
PAT Margin (%) ⁽¹⁴⁾	17.21%	16.33%	15.30%	12.35%	18.19%
ROCE (%) ⁽¹⁵⁾	9.55%*	9.63%*	17.47%	16.07%	26.78%
ROE (%) ⁽¹⁶⁾	11.64%*	11.38%*	20.68%	18.25%	35.82%
Net debt (INR Mn) ⁽¹⁷⁾	6,805.26	5,796.77	5,790.63	6,100.87	4,756.35
Debt to Equity ratio ⁽¹⁸⁾	0.58	0.62	0.61	0.73	0.79
Gross block per bed (INR Mn) ⁽¹⁹⁾	3.65	3.25	3.44	3.19	2.07
Fixed Asset Turnover Ratio ⁽²⁰⁾	0.76*	0.73*	1.43	1.70	2.66







*Not Annualized

1. Bed capacity is as at end of the relevant year and denotes the number of beds for which the civil structure has been planned for. 2. Number of operational beds includes census beds (beds available for mid-night occupancy such as ICUs and wards) and non-census beds (all other beds available other than census beds, such as day-care beds and casualty beds). 3. Number of ICU beds represents the total ICU beds operational as of the end of the relevant year. 4. Bed occupancy rate is calculated by dividing the total number of occupied beds by the total number of operational beds. 5. ARPOB is calculated as revenue from sale of services - healthcare divided by number of occupied bed days in the relevant year. 6. ALOS is calculated as the average number of days spent by admitted in-patients in the relevant year. 7. In-patient volume refers to the total number of patients who have been admitted to a healthcare facility for treatment and subsequently discharged in the relevant year. 8. Out-patient volume refers to the total number of out-patient visits for consultations within the relevant year. 9. In-patient revenue refers to the income generated from patients who are admitted to the hospital for at least one overnight stay during the relevant year. 10. Out-patient revenue includes revenue earned from services provided to patients who visit the hospital or clinic for treatment during the relevant year, but do not require an overnight stay. 11. Revenue from operations includes revenue from sale of services from in-patient and out-patient hospital receipts and other operating revenue. 12. EBITDA is calculated as profit or loss before tax (excluding other income) for the year plus finance costs, depreciation and amortization expense and before exceptional items. 13. EBITDA Margin is calculated as EBITDA divided by revenue from operations. 14. PAT Margin (%) is calculated as restated profit after tax divided by revenue from operations. 15. RoCE is calculated as a percentage of EBIT (before exceptional items) divided by capital employed. EBIT is calculated as profit for the year plus tax expenses and finance costs and excluding Other Income. Capital employed is calculated as sum of total equity plus total borrowings, total lease liabilities, deferred tax liabilities, less deferred tax assets. 16. RoE is calculated as restated profit for the period divided by average total equity. Average total equity is calculated as the sum of opening total equity at the beginning of the year and closing total equity at the end of the year, divided by two. 17. Net debt is total debt less cash and cash equivalents. Total debt includes current and non-current borrowings and lease liabilities. 18. Debt to equity ratio is calculated as total debt divided by total equity. 19. Gross block per bed is calculated by dividing the gross block of assets (including right to use of assets) of each hospital by the total bed capacity of such hospital as of the end of the relevant year. 20. Fixed Asset Turnover Ratio is calculated by dividing the Revenue from Operation by the average gross block of assets (including right to use of assets).

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

For details of our other operating metrics disclosed elsewhere in the Red Herring Prospectus, see “Our Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” at pages 274 and 448, respectively.

Market Share: We are the second largest private hospital chain in North India with an aggregate bed capacity of 3,000 beds, and the largest private hospital chain in terms of bed capacity in Haryana with 1,600 beds located in the state as of March 31, 2025. (Source: CRISIL Report)

Intellectual property: As on the date of the Red Herring Prospectus, our Company and Subsidiaries are using five trademarks including the logos  and , which are registered in the name of our Promoter, Dr. Ajit Gupta. Our Promoter, Dr. Ajit Gupta issued non-objection certificates dated August 29, 2022 and October 12, 2011 for (i) use of the logo , and; (ii) for use of the word marks ‘Park Hospital’ and ‘Park’ by our Company and Subsidiaries, respectively. Further, our Promoter, Dr. Ajit Gupta issued a non-objection certificate dated November 26, 2019 for use the logo  and the word mark ‘The Signature’ by our Subsidiary, Park Medicity North. Further, the logo  is registered in the name of our Material Subsidiary, RGS. Furthermore, the logo  is registered in the name of our Material Subsidiary, Narsingh Hospital.

Employee strength: As of September 30, 2025, we had a team of 1,014 doctors, 2,142 nurses, 730 medical professionals and 2,025 support staff across our hospitals. For details, see “Our Business—Human Resources” on page 294 of the RHP.

BOARD OF DIRECTORS

Sr. No	Name	Designation	Experience and Educational Qualification	Other Directorships
1.	Dr. Ajit Gupta	Chairman and a Whole-Time Director	He holds a bachelor’s degree in medicine and surgery from the University College of Medical Sciences, University of Delhi. He is registered with the Medical Council of India since January 8, 1981 (i.e. 44 years ago) Prior to joining our Company, he was associated with Safdarjung Hospital as a junior resident and with Park Hospital and Sunil Nursing Home as a sole proprietor. He has more than 25 years of experience in nursing home and hospital business.	Indian companies: <ul style="list-style-type: none"> Blue Heavens Health Care Private Limited; Healcare Health Infra Private Limited; Park Medicenters and Institutions Private Limited; Healplus Health Services Private Limited; Healplus Labs Private Limited; Umkal Health Care Private Limited; Park Medicity India Private Limited; Narsingh Hospital and Heart Institute Private Limited; R G S Healthcare Limited; and Devina Derma Private Limited Foreign companies: Nil
2.	Dr. Ankit Gupta	Managing Director	He holds a bachelor’s degree in medicine and surgery from the Bharati Vidyapeeth Deemed University, Pune. He registered with the Delhi Medical Council on March 14, 2005. Prior to joining our Company, he has been associated with Park Hospital as head-operations He has been associated with our Company since January 20, 2011 (except for a period of two months from May 10, 2024 to July 10, 2024). He has more than 20 years of experience in the medical profession.	Indian companies: <ul style="list-style-type: none"> Ratangiri Innovations Private Limited; Healcare Health Infra Private Limited; Aggarwal Hospital and Research Services Private Limited; Park Medicenters and Institutions Private Limited; Healplus Health Services Private Limited; Park Medicity (North) Private Limited; Healplus Labs Private Limited; DMR Hospitals Private Limited; Kailash Super-Speciality Hospital Private Limited; and Park Medicity (World) Private Limited. Foreign companies: Nil
3.	Dr. Sanjay Sharma	Whole Time Director and Chief Executive Officer	He holds a bachelor’s degree in medicine and surgery from the University of Delhi. He registered with the Medical Council of India on June 1, 1988. He has been associated with the Park Group of Hospitals since January 2, 2014 and was designated as the Chief Executive Officer of our Company on November 15, 2024. Prior to joining our Company, he was associated with Talwar Medical Centre as a resident medical officer, Jamia Hamdard (Majeedia Hospital) as a resident medical officer, Jet Airways (India) Limited as a doctor, Curls & Curves (I) Limited as a resident doctor, East West Medical Center as a general duty resident medical officer, SITA Inbound Division (a division of Kuoni Travel (India) Private Limited) as a team manager, Fortis Flt. Lt. Rajan Dhall Hospital as general manager- head of sales and marketing, SevenHills Healthcare Limited as vice president- marketing, and Alchemist Hospitals Limited as the chief operating officer. He has more than 20 years of experience in the medical industry.	Indian companies: <ul style="list-style-type: none"> Global Special Springs Private Limited; DMR Hospitals Private Limited; Narsingh Hospital & Heart Institute Private Limited; Park Medical Centre Private Limited; Park Medicity (Haryana) Private Limited; and Park Medicity (NCR) Private Limited. Foreign companies: Nil
4.	Ravi Krishan Takkar	Non- Executive Independent Director	He holds a bachelor’s degree in commerce, bachelor’s degree in law from the University of Delhi and a post graduate diploma in bank management from National Institute of Bank Management. He is an associate member of the Indian Institute of Bankers. He has been associated with our Company since May 6, 2024. Prior to joining our Company, he was associated with Oriental Bank of Commerce as an executive director, Dena Bank as an executive director, and UCO Bank as the managing director and chief executive officer. He has more than 39 years of experience in the banking and management industry.	Indian companies: <ul style="list-style-type: none"> Nabsamruddhi Finance Limited; and LIC Housing Finance Limited. Foreign companies: Nil

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Sr. No	Name	Designation	Experience and Educational Qualification	Other Directorships
5.	Munish Sibal	Non- Executive Independent Director	He holds a master's degree in science (defence studies) from the Faculty of Science, University of Madras and a master's degree in philosophy (defence and management studies) from School of Defence and Management Studies, Faculty of Management Studies, Devi Ahilya Vishwavidyalaya, Indore. He has also completed the 45th national security and strategic studies course from National Defence College, New Delhi and independent director's programme on corporate governance for senior officers of armed forces from Management Development Institute, Gurgaon, Haryana. He has been associated with our Company since May 31, 2024. Prior to joining our Company, he was associated with the Indian Armed Forces for a period of more than 38 years, with Lieutenant General of the Indian Armed Forces being his last held position. He has also served as the president of the Equestrian Federation of India and vice-president and army chief steward of the Indian Polo Association. He is the recipient of the Param Vishisht Seva Medal and the Ati Vishisht Seva Medal.	Indian companies: • Park Medicenters and Institutions Private Limited. Foreign companies: Nil
6.	Dr. Kamlesh Kohli	Non- Executive Independent Director	She holds a bachelor's degree in medicine and surgery from the University of Delhi and a post graduate degree in doctor of medicine (pharmacology) from University of Delhi. She is associated with the International Medical Sciences Academy as a fellow member. She has been associated with the Company since May 31, 2024. Prior to joining our Company she was associated with Sudha Rustagi College of Dental Sciences and Research as professor and head in department of pharmacology, Medical Council of India as whole time inspector, University College of Medical Sciences, University of Delhi as a lecturer, Shri Guru Ram Rai Institute of Medical and Health Sciences/Shri Mahant Indresh Hospital as professor cum advisor to chairman in the department of pharmacology. She has more than 17 years of experience in the medical industry. She was also previously appointed as an advisor at BP Koirala Institute, Nepal on behalf of the Government of India, by way of an appointment letter dated April 30, 2004 for a period of three years. She is the recipient of the Distinguished Teacher of State Award from the Delhi Medical Association.	Indian companies: • Park Medicenters and Institutions Private Limited; and • Park Medicity India Private Limited. Foreign companies: Nil

For further details, see "Our Management" on page 329 of the RHP.

OBJECTS OF THE OFFER

The Offer comprises of the Fresh Issue of up to [●] Equity Shares of face value of ₹2 each, aggregating up to ₹ 7,700.00 million by our Company and an Offer for Sale of up to [●] Equity Shares of face value of ₹2 each, aggregating up to ₹ 1,500.00 million by the Promoter Selling Shareholder.

Offer for Sale

The proceeds of the Offer for Sale shall be received by the Promoter Selling Shareholder. Our Company will not receive any proceeds from the Offer for Sale. The Promoter Selling Shareholder will be entitled to the Offer Proceeds, to the extent of the Equity Shares offered by him in the Offer, net of his share of the Offer related expenses. Accordingly, the Offer for Sale will not form a part of the Net Proceeds. For further details of the Offer for Sale, see "The Offer" on page 81 of the RHP.

Objects of the Offer

Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards the following objects:

1. Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries;
2. Funding capital expenditure for development of new hospital by our Subsidiary, Park Medicity (NCR);
3. Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens and Ratangiri; and
4. Unidentified inorganic acquisitions and general corporate purposes.

(collectively, referred to herein as the "Objects").

The main objects clause and the objects incidental and ancillary to the main objects clause set out in the Memorandum of Association enable us to undertake (i) our existing business activities; (ii) the activities proposed to be funded from the Net Proceeds; and (iii) the activities for which: (a) the borrowings proposed to be repaid/ prepaid from the Net Proceeds were utilised; and (b) the funds earmarked for unidentified inorganic acquisitions and general corporate purposes shall be used. Further, our Company expects to receive the benefits of listing of the Equity Shares on the Stock Exchanges, including the enhancement of our visibility and brand image among our existing and potential customers and creation of a public market for our Equity Shares in India.

Net Proceeds

The following table sets forth details of the Net Proceeds:

(in ₹ million)

Particulars	Estimated amount
Gross Proceeds of the Fresh Issue ⁽¹⁾	7,700.00
(Less) Offer related expenses to be borne by our Company ⁽²⁾⁽³⁾	([●])
Net proceeds from the Fresh Issue ("Net Proceeds") ⁽¹⁾	[●]

(1) Subject to full subscription to the Fresh Issue.

(2) To be determined after finalisation of the Offer Price and updated in the Prospectus prior to filing with the RoC.

(3) For details see "- Offer related expenses" below on page 146 of the RHP.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Requirement of funds and utilisation of Net Proceeds

The Net Proceeds are proposed to be utilised in the following manner:

(in ₹ million)

Sr. No.	Particulars	Estimated amount
1.	Repayment/ prepayment, in full or in part, of outstanding borrowings availed by our Company and our Subsidiaries	3,800.00
2.	Funding capital expenditure for development of new hospital by our Subsidiary Park Medicity (NCR)	605.00
3.	Funding capital expenditure for purchase of medical equipment by our Company and our Subsidiaries, Blue Heavens and Ratangiri	274.59
4.	Unidentified inorganic acquisitions and general corporate purposes*	●#
	Total*	●

To be finalised upon determination of the Offer Price and updated in the Prospectus prior to filing with the RoC. The amount to be utilised for general corporate purposes and unidentified inorganic acquisition shall not exceed 35% of the Gross Proceeds. The amount to be utilised for each of (i) unidentified inorganic acquisition; and (ii) general corporate purposes shall not exceed 25% of the Gross Proceeds

* To be finalised upon determination of the Offer Price and updated in the Prospectus prior to filing with the RoC.

Means of finance: The fund requirements set out in the aforesaid Objects are proposed to be met from the Net Proceeds and internal accruals. Accordingly, our Company confirms that there is no requirement to make firm arrangements of finance through verifiable means towards at least 75% of the stated means of finance, excluding the amount to be raised from the Offer and existing identifiable accruals as required under the SEBI ICDR Regulations. In case of a shortfall in the Net Proceeds or any increase in the actual utilization of funds earmarked for the Objects, our Company may explore a range of options including utilizing our internal accruals and/ or seeking additional debt from existing and/ or other lenders.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilisation of issue proceeds of past public offers / rights issues, if any, of our Company in the preceding 10 years: Not Applicable.

Terms of issuance of convertible security, if any: Not Applicable.

Name of Monitoring Agency: CRISIL Ratings Limited

Shareholding Pattern as on the date of the RHP:

Category of shareholder	Pre-Offer number of Equity Shares (Number of fully paid-up Equity Shares held)	% Holding of Pre-Offer Shareholding
Promoters and Promoter Group	367,307,766	95.55
Public	17,092,234	4.45
Total	384,400,000	100.00

SUMMARY OF RESTATED CONSOLIDATED FINANCIAL INFORMATION

The following details are derived from the Restated Consolidated Financial Information:

(₹ in million, unless specified)

Particulars	As at and for the six months ended September 30, 2025	As at and for the six months ended September 30, 2024	As at and for the Financial Year ended March 31, 2025	As at and for the Financial Year ended March 31, 2024	As at and for the Financial Year ended March 31, 2023
Equity Share capital (A)	768.80	768.80	768.80	768.80	768.80
Instruments in the nature of Equity (B)	-	-	-	-	-
Other equity (C) ⁽¹⁾	11,239.00	9,131.27	9,927.03	8,059.15	6,096.81
Total Equity (D=A+B+C)	12,007.80	9,900.07	10,695.83	8,827.95	6,865.61
Total Income ⁽²⁾	8,233.94	7,074.77	14,259.74	12,630.84	12,721.77
Restated Profit for the year ⁽³⁾	1,391.43	1,128.81	2,132.07	1,519.96	2,281.70
Earnings per share (basic) (₹)	3.62	2.94	5.55	3.95	5.94
Earnings per share (Diluted) (₹)	3.62	2.94	5.55	3.95	5.94
Net Asset Value per Equity Share (₹) ⁽⁴⁾	30.00	24.02	26.58	21.23	17.37
Total borrowings ⁽⁵⁾	7,339.11	6,489.62	6,820.67	6,867.13	5,756.81
Net worth ⁽⁶⁾	11,530.46	9,231.89	10,218.64	8,159.77	6,675.49

Notes: 1. Other equity includes revaluation reserves and capital reserves. 2. Total income includes revenue from operation as well as other income also. 3. Restated profit for the year is inclusive of other comprehensive income. 4. Net Asset Value is computed as the Equity attributable to owners of the company at the end of year divided by the equity shares outstanding as on end of year (adjusted for any bonus or split of equity shares, as applicable). Equity attributable to owners means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account (i.e. excluding revaluation reserves and capital reserves) for the relevant year. 5. Total borrowing included current & non-current lease liabilities along with borrowings. 6. Net worth means the aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the Restated Consolidated Financial Information, but does not include reserves created out of revaluation of assets write-back of depreciation and amalgamation as per Regulation 2(1)(hh) of the SEBI ICDR Regulations.

For further details, see "Restated Consolidated Financial Information" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" on pages 349 and 448 of the RHP respectively.

INTERNAL RISK FACTORS

Below mentioned risks are the top 5 risk factors as per the RHP. For further details, see "Risk Factors" on page 35 of the RHP.

1. We have certain contingent liabilities that have been disclosed in our financial statements. As of September 30, 2025, our contingent liabilities (excluding corporate guarantees) constituted 11.66% of our net worth, while corporate guarantees given by our Company and Subsidiaries constituted 71.58% of our net worth. If these liabilities materialize, they may adversely affect our results of operations, cash flows and financial condition.
2. Any downgrade in our credit ratings could increase borrowing costs, which could in turn adversely affect our borrowing cost, our business, results of operations, financial condition and cash flows.
3. We witnessed a decline in our revenue from operations and restated profit after tax, as well as an increase in our cost of materials consumed / services rendered, in Fiscal 2024 as compared to Fiscal 2023. A similar decline in revenue from operations and restated profit after tax or increase in costs may adversely affect our business, financial condition, results of operations and cash flows.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

4. We are highly dependent on doctors, nurses, medical professionals and support staff. As of September 30, 2025, the attrition rate of our doctors was 33.72%. If we are unable to retain or attract such professionals, our business, results of operations and financial condition may be adversely affected.
5. A significant portion of our revenue from operations is derived from our hospitals located in Haryana, which comprised 69.06%, 74.62%, 73.43%, 76.92%, and 83.91% of our revenue from operations in the six months ended September 30, 2025 and September 30, 2024, and Fiscals 2025, 2024 and 2023, respectively. Any adverse developments at these hospitals or in this state could have an adverse effect on our business, results of operations and financial condition.

SUMMARY OF OUTSTANDING LITIGATION, CLAIMS AND REGULATORY ACTION

- A. A summary of outstanding litigation proceedings involving our Company, Directors, Promoters, Subsidiaries, Key Managerial Personnel and members of Senior Management as on the date of the Red Herring Prospectus, in accordance with the SEBI ICDR Regulations and the Materiality Policy, is provided below:

Name of Entity	Criminal proceedings	Tax proceedings	Statutory or regulatory proceedings	Disciplinary actions by the SEBI or Stock Exchanges against our Promoters	Material civil litigations [#]	Aggregate amount involved (in ₹ million)*
Company						
By our Company	Nil	Nil	NA	NA	Nil	Nil
Against our Company	1	1	1	NA	Nil	44.03
Directors[§]						
By our Directors	2	Nil	NA	NA	Nil	Nil
Against our Directors	2	5	1	NA	Nil	6.37
Promoters						
By our Promoters	2	Nil	NA	NA	Nil	Nil
Against our Promoters	2	5	1	Nil	Nil	6.37
Subsidiaries						
By our Subsidiary(ies)	Nil	Nil	NA	NA	1	Nil
Against our Subsidiary(ies)	1	23	2	NA	Nil	1,300.91
Key Managerial Personnel[§]						
By our Key Managerial Personnel	3	NA	NA	NA	NA	NA
Against our Key Managerial Personnel	2	NA	1	NA	NA	NA
Senior Management						
By members of our Senior Management	1	NA	NA	NA	NA	NA
Against members of our Senior Management	Nil	NA	Nil	NA	NA	NA

* To the extent quantifiable.

§ Including Directors who are Promoters.

Determined in accordance with the Materiality Policy.

- B. Brief details of top five material outstanding litigation / legal proceedings initiated against the Company and amount involved:

S. No.	Particulars	Litigation filed by	Current status	Amount involved (in ₹ million)
1.	The Employee State Insurance Corporation ("ESIC") issued a show cause notice dated February 15, 2016 and further filed a criminal complaint against our Company and our Promoters, Dr. Ajit Gupta and Dr. Ankit Gupta on December 22, 2016 before Karkardooma Courts, Delhi, for allegedly not obtaining the registration under ESI Act and the matter was listed for further proceedings. Aggrieved by the same our Company and our Promoters, Dr. Ajit Gupta and Dr. Ankit Gupta filed criminal miscellaneous application against ESIC before the High Court of Delhi, under section 482 of Code of Criminal Procedure, alleging that the Company is not required to obtain the registration under ESI Act, because while the Ministry of Labour and Employment issued a notification through which medical institutions were brought under the purview of Employee State Insurance Act, 1948 on March 23, 2011, pursuant to the various writ petitions filed by hospitals & nursing homes employee federation and Delhi Medical Association ("DMA"), before the High Court of Delhi, interim relief was awarded to the medical institutions from obtaining registration under ESIC, till the pendency of writ petitions. Our Company was also a member of DMA and a party to the writ petition filed by DMA. The matter is currently pending.	ESIC	Pending	Non-quantifiable

- C. Regulatory Action, if any – disciplinary action taken by SEBI or Stock Exchanges against the Promoters in last 5 financial years including outstanding action, if any: Nil

- D. Brief details of outstanding criminal proceedings against our Promoters:

1. A criminal complaint was filed by the Employee State Insurance Corporation ("ESIC") against our Promoters, Dr. Ajit Gupta and Dr. Ankit Gupta. For further details, see "Litigation involving our Company - Litigation against our Company - Criminal Litigation" on page 484 of the RHP.
2. A criminal complaint was filed by Kuldeep Parashar against our Promoters, Dr. Ajit Gupta and Dr. Ankit Gupta. For further details, see "Litigation involving our Subsidiaries – Litigation against our Subsidiaries- -Criminal Litigation" on page 486 of the RHP.

For further details of the outstanding litigation matters, see "Outstanding Litigation and Material Developments" on page 483 of the RHP.

ANY OTHER IMPORTANT INFORMATION AS PER BRMLs / COMPANY - NIL

DECLARATION BY OUR COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act and the rules, regulations and guidelines issued by the Government of India and the rules, regulations and guidelines issued by the SEBI, established under Section 3 of the SEBI Act, as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SCRR, the SEBI Act, each as amended or the rules made or guidelines or regulations issued thereunder, as the case may be. We further certify that all statements made in the Red Herring Prospectus are true and correct.

DECLARATION BY PROMOTER SELLING SHAREHOLDER

The Promoter Selling Shareholder, hereby confirm that all statements, disclosures and undertakings specifically made or confirmed by me in the Red Herring Prospectus about or in relation to myself, as a Promoter Selling Shareholder, and the Offered Shares, are true and correct. We assume no responsibility as a Promoter Selling Shareholder, for any other statements, disclosures or undertakings including any of the statements, disclosures or undertakings made or confirmed by the Company or any other person(s) in the Red Herring Prospectus.